2900-62-1

Upstream product

• 6183-33-1 2,4-Dinitro-benzoesaeure-vinylester 
• 19081-19-7 2,4-dinitro-benzoic acid phenyl ester 
• 610-30-0 2,4-dinitrobenzoic acid 
• 18959-17-6 2,4-dinitro-benzoic acid methyl ester 

Downstream Products

• 99411-87-7 2,4-Dinitro-benzoic acid [(E)-1,2-dimethyl-3-(2-phenyl-2H-[1,2,3]triazol-4-yl)-prop-2-en-(E)-ylidene]-hydrazide 
• 258264-15-2 ethyl 4-(2-(2,4-dinitrophenyl)hydrazono)piperidine-1-carboxylate 
• 1374607-43-8 N-(9-(2-(benzyloxy)phenyl)-1,2,3,4,5,6,7,8-octahydro-3,3,6,6-tetramethyl-1,8-dioxoacridin-10(9H)-yl)-2,4-dinitrobenzamide 
• 1374607-44-9 N-(9-(3-(benzyloxy)phenyl)-1,2,3,4,5,6,7,8-octahydro-3,3,6,6-tetramethyl-1,8-dioxoacridin-10(9H)-yl)-2,4-dinitrobenzamide 
• 1374607-45-0 N-(9-(4-(benzyloxy)phenyl)-1,2,3,4,5,6,7,8-octahydro-3,3,6,6-tetramethyl-1,8-dioxoacridin-10(9H)-yl)-2,4-dinitrobenzamide 
• 313276-21-0 2-(2,4-dinitrophenyl)-5-phenyl-1,3,4-oxadiazole 

Relevant academic research and scientific papers

New piperidine-hydrazone derivatives: Synthesis, biological evaluations and molecular docking studies as AChE and BChE inhibitors

Hydrazones and the piperidine ring containing compounds were considered as beneficial substrates in drug design. Therefore, this study was aimed at the synthesis of new benzoyl hydrazones derived from ethyl 4-oxopiperidine-1-carboxylate and 2,6-diphenylpiperidin-4-one. The synthesized compounds (1?19) were screened for their antioxidant, anticholinesterase and anticancer activities. The antioxidant capacity of the compounds was evaluated by using four complementary tests. The results showed that compound 7 and 17 have the higher lipid peroxidation inhibitory activity than the other compounds. In DPPH˙ scavenging assay, compounds 5, 6, 10, 14, 17 demonstrated better activity than that of standard BHT, while in ABTS+˙ scavenging assay compound 6 and 17 exhibited better activity among the other compounds. The CUPRAC assay disclosed that compound 2 displayed better activity than α-tocopherol. The anticholinesterase activity was performed against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. Compound 11 (IC50: 35.30?±?1.11?μM) inhibited BChE better than galantamine (IC50: 46.03?±?0.14?μM). We conclude that the compound 11 can be considered as a candidate for BChE inhibitor. Moreover docking method was applied to elucidate the AChE and BChE inhibitory mechanism of the compound 11. Molecular docking analysis revealed that compound 11 bound to BChE enzyme more efficiently when compared to the AChE due to its orientations and different types of interactions. In addition, the non-cytotoxic properties of the compounds brought them into prominence, although they did not show significant anticancer properties.

Synthesis, Characterization and Energetic Properties of 1,3,4-Oxadiazoles

An efficient cyclization between nitro-substituted benzoic acids and nitro-substituted benzohydrazides affords 1,3,4-oxadiazoles. Facile synthesis and a broad substrate scope produce a range of compounds, some of them with potential as high-energy compounds. Heats of formation (ΔHf) and densities (ρ) were calculated, and heats of decomposition (ΔHd) and combustion (ΔHc) were determined experimentally. The densities of seven of the synthesized compounds were determined by gas pycnometry, and the respective values of detonation velocity (VD), detonation pressure (PD) and specific impulse (ISP) were calculated using the EXPLO5 program. An X-ray structure of 2-(2,4-dinitrophenyl)-5-(3,5-dinitrophenyl)-1,3,4-oxadiazole (4n) revealed the non-planarity of the molecule and afforded a crystal density of 1.698 (at 120 K), close to the pycnometric value of 1.64 at room temperature. Efficient cyclization between nitro-substituted benzohydrazides and nitro-substituted benzoic acids affords energetic 1,3,4-oxadiazoles.